about
DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected]Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsThe impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers.Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials.Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma.Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.Oral prevalence and clearance of oncogenic human papilloma virus in a rehabilitation community for substance abusers in Italy: a case of behavioral correction?Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors.The Glaucoma Italian Pediatric Study (GIPSy): 1-Year Results.The prognostic role of tumor size in early breast cancer in the era of molecular biology.Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International ExtranSudden Death in End Stage Renal Disease: Comparing Hemodialysis versus Peritoneal Dialysis.Olfactory system of highly trained dogs detects prostate cancer in urine samples.Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases.Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse.Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition ActivityBest practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM)Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitorsAssessing assumptions for statistical analyses in randomised clinical trialsPan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE ProjectGadoxetate Disodium-Enhanced MR Cholangiography for Evaluation of Biliary-Enteric Anastomoses: Added Value Beyond Conventional T2-Weighted ImagesThe prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trialsCombined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of ProgressionStandard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trialNeoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE studyRE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and PrognosisHER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal CancerChoosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave outMetronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 studyAssessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpointPrognostic nutritional index as a prognostic marker in glioblastoma: Data from a cohort of 282 Italian patientsMetastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH projectAntibiotics versus surgery for appendicitis
P50
Q24339462-D70A38B4-68CF-43A8-A9CB-F4CA10CC119AQ27853380-752C9C75-DA77-4370-98F9-9EF5D4844100Q30249696-B66A35FC-4219-49E5-A85E-C07D87EB1253Q37143748-BD4590A8-CC64-405E-B71D-F097D83780DDQ38151305-BCBCF55E-1E73-41F5-91D0-94150A76286BQ38293725-C7DAD3D1-0357-4A43-BE36-A2FA3E720276Q38677321-E61716A0-F30F-4516-B860-3020913F2F8CQ38862060-8269935E-AB24-416D-9FC0-4AA4C2891735Q38968452-E271ABC8-2FEB-4FF6-A37B-C5A2C0B71C66Q41116967-866753F5-E006-4F48-8502-A76BF7AE4DBAQ41555316-4911FFAC-9B1A-4D9B-BC44-E2FE3E471CFCQ41658902-1C494E5C-27CD-497D-88FE-F8077B3944E9Q44687326-A39349E3-B8BB-4DCB-BE3E-E1ACD0576E94Q45040467-634603B2-D36D-4F7A-BD4E-A86AA488C3AFQ47108028-39E82018-B926-43EA-A3E2-AE19B668101FQ48008882-561B7487-8AF3-4C23-8D93-EEAFFBB44299Q50758909-6512A66C-106A-46B1-ACB3-C1A18B166E30Q51110465-AFCA3FFB-BC40-4470-BA37-890A8DBC154EQ53816072-8AAAAF31-7E1D-483F-B8DC-E60917A4E581Q54388409-809AEF88-F9B2-4A84-A0D8-B9217673A7A0Q57461720-71B0A782-8E52-4B4D-8203-90742737277DQ58581973-DCB453FC-4938-453A-B20D-8EAC90CFDD53Q58694191-7AE0B5F4-437D-416E-AC82-745977CDA111Q64094662-F08A7AB9-9E91-4466-871A-044C8E7CDBD7Q64111829-001808A9-573A-4AC4-828F-58482481A6D1Q90627608-9801D5BE-7D93-41F5-B14E-8B8FA6727D16Q91821168-DE60F587-D788-40D4-AD94-7B3CDE51EF9FQ91850228-264D095C-3508-4B85-8E0C-23A606F3F666Q91903136-9DEB7158-93FC-4F43-8D29-A99B63B67777Q92015947-CF650747-968A-42D9-B77E-90BB4D18BA7FQ92086321-95528242-B92D-435C-9BB8-928E32970CB1Q92476216-EE4DB26F-6AF3-4A4F-B936-DB879D0A6246Q92672254-BDD11724-1D9A-4B64-B1B2-D8F6983D34B5Q92885759-738A82CF-1520-4D9B-BAB2-6557B990AF10Q92897874-DD83D858-51D5-41D1-A38A-502936180CD0Q93014348-1D21E03D-3710-4B74-B254-4D4888F2262AQ93016783-028D35B3-20D0-4463-B207-E887CD541080Q93029361-30ABA42F-EEF0-471D-9E71-39FF27BE28EFQ93258278-613BB614-9FA0-4AEE-9CC7-D5B0FA7A7F4DQ95389196-7EE5C50A-8847-483E-B6F1-1D9A541E2B2F
P50
description
researcher (ORCID 0000-0001-9541-9354)
@en
name
Valter Torri
@en
type
label
Valter Torri
@en
prefLabel
Valter Torri
@en
P31
P496
0000-0001-9541-9354